Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 15/20 | 0.38 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398928 | 0.93 | MAOB (0.38) | SLC6A4SLC6A2SLC6A3MAOB | |
| Fumaric Acid SCHEMBL1936564 | 0.91 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL1936506 | 0.91 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL1937050 | 0.86 | OPRM1 (0.35) | HRH1 | |
| SCHEMBL1936078 | 0.83 | PDK1 (0.41) | SLC6A4SLC6A2SLC6A3MAOB | |
| SCHEMBL2396274 | 0.83 | PDK1 (0.39) | SLC6A4SLC6A2SLC6A3MAOB | |
| Fumaric Acid SCHEMBL1936479 | 0.81 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HRH1 | |
| Fumaric Acid SCHEMBL27834011 | 0.81 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL2388946 | 0.81 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2391914 | 0.78 | OPRM1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| EP-2331505-A2 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A2 2/4885HRH1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.